{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:09:28Z","timestamp":1762603768352},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1097\/wnf.0b013e3182560401","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T12:57:57Z","timestamp":1337173077000},"page":"97-102","source":"Crossref","is-referenced-by-count":8,"title":["Combination Treatment With Aripiprazole and Valproic Acid for Acute Mania"],"prefix":"10.1097","volume":"35","author":[{"given":"Hyun-Ghang","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Kwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4088\/JCP.v64n0610","article-title":". Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method.","volume":"64","author":"Post","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4088\/JCP.v61n0104","article-title":". The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.","volume":"61","author":"Frye","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R3-1-20210203","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1192\/bjp.187.3.235","article-title":". Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial.","volume":"187","author":"Vieta","year":"2005","journal-title":"Br J Psychiatry"},{"key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00004714-200004000-00012","article-title":". Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.","volume":"20","author":"Muller-Oerlinghausen","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl 3","key":"R6-1-20210203","first-page":"28","article-title":"Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder.","volume":"66","author":"McIntyre","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1177\/0269881108098820","article-title":". A UK consensus on the administration of aripiprazole for the treatment of mania.","volume":"23","author":"Aitchison","year":"2009","journal-title":"J Psychopharmacol"},{"key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/14656566.8.7.1001","article-title":". Aripiprazole: pharmacology and evidence in bipolar disorder.","volume":"8","author":"McIntyre","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":". Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R10-1-20210203","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/026988110401800308","article-title":". Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.","volume":"18","author":"Hirose","year":"2004","journal-title":"J Psychopharmacol"},{"key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejphar.2003.10.025","article-title":". In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.","volume":"483","author":"Jordan","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R12-1-20210203","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1176\/appi.ajp.2008.07101560","article-title":". Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproatelithium monotherapy: a placebo-controlled study.","volume":"165","author":"Vieta","year":"2008","journal-title":"Am J Psychiatry"},{"key":"R13-1-20210203","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1399-5618.2011.00898.x","article-title":". Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study.","volume":"13","author":"Marcus","year":"2011","journal-title":"Bipolar Disord"},{"key":"R15-1-20210203","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1440-1819.1995.tb01895.x","article-title":"Current topics in tardive dyskinesia in Japan.","volume":"49","author":"Inada","year":"1995","journal-title":"Psychiatry Clin Neurosci"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":". A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients.","volume":"166","author":"Day","year":"1995","journal-title":"Br J Psychiatry"},{"key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","article-title":". Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.","volume":"59","author":"Tohen","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":". Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R20-1-20210203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":". Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.","volume":"182","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1399-5618.2004.00115.x","article-title":". Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study.","volume":"6","author":"Sachs","year":"2004","journal-title":"Bipolar Disord"},{"key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/01.jcp.0000144887.66319.2f","article-title":". Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania.","volume":"24","author":"Yatham","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1176\/appi.ajp.160.9.1651","article-title":". A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jad.2008.05.014","article-title":". Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.","volume":"112","author":"Keck","year":"2009","journal-title":"J Affect Disord"},{"key":"R25-1-20210203","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1177\/0269881106059693","article-title":". Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.","volume":"20","author":"Sachs","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R26-1-20210203","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740330902835493","article-title":"A review of the safety and tolerability of aripiprazole.","volume":"8","author":"Pae","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"R27-1-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/JCP.0b013e31819a8dbe","article-title":". Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.","volume":"29","author":"Henderson","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"R28-1-20210203","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.56.2.172","article-title":". Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy.","volume":"56","author":"Biton","year":"2001","journal-title":"Neurology"},{"key":"R29-1-20210203","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0149-2918(02)80061-3","article-title":". Changes in body weight and body mass index among psychiatric patients receiving lithium, valproate, or topiramate: an open-label, nonrandomized chart review.","volume":"24","author":"Chengappa","year":"2002","journal-title":"Clin Ther"},{"key":"R30-1-20210203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1600-0404.1984.tb00804.x","article-title":". Weight gain during treatment with valproate.","volume":"70","author":"Dinesen","year":"1984","journal-title":"Acta Neurol Scand"},{"key":"R31-1-20210203","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1111\/j.1467-789X.2010.00800.x","article-title":". Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.","volume":"12","author":"Verrotti","year":"2011","journal-title":"Obes Rev"},{"key":"R32-1-20210203","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00023210-200822050-00002","article-title":". Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.","volume":"22","author":"Pae","year":"2008","journal-title":"CNS Drugs"},{"key":"R33-1-20210203","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4088\/JCP.v64n0910","article-title":". Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.","volume":"64","author":"Pigott","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R34-1-20210203","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1185\/03007991003779380","article-title":". Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithiumvalproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.","volume":"26","author":"Vieta","year":"2010","journal-title":"Curr Med Res Opin"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-201205000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:52:48Z","timestamp":1618278768000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201205000-00001"}},"subtitle":["An 8-Week, Single-Blind, Randomized Controlled Trial"],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3182560401","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}